Avista Public Acquisition Corp. II (NASDAQ:AHPA) has entered into a definitive agreement to acquire Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to spin-off its antibody discovery business OmniAb, Inc. at a pre-money equity valuation of $850 million. The San-Diego based biopharmaceutical company is focused on developing technologies that help pharmaceutical companies discover medicine. Ligand’s OmniAb platform provides Read More
To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.
As the Coronavirus (COVID-19) outbreak continues to spread across the globe, there have been over 118,000 cases and more than 4,000 deaths attributed...
As the Coronavirus (COVID-19) outbreak continues to spread across the globe, there have been over 118,000 cases and more than 4,000 deaths attributed...
